Haselmeier Announces the CE Mark for JuniorSTAR® Half-Unit Insulin Pen

(PresseBox) ( Stuttgart, )
Haselmeier has announced the CE Mark of JuniorSTAR® by Sanofi. JuniorSTAR® is a new easy-to-use, half‑unit insulin reusable pen that can be used with Lantus® (insulin glargine), Apidra® (insulin glulisine) or Insuman® (recombinant human insulin). Developed and manufactured by Haselmeier, JuniorSTAR® is a light weight reusable pen with a large dose display, single-step dial back without insulin leakage and delivers from 1 to 30 units per injection.

"Haselmeier is proud to partner with Sanofi on this important program to develop and manufacture JuniorSTAR® and we look forward to continuing our business relationship in the future." said Frédéric Gabriel, General Manager of Haselmeier.

Director Project Management at Haselmeier, Sandra de Haan adds that "the excellent cooperation between Sanofi and Haselmeier project teams ensured announcement to the diabetes community at the recent EASD congress."

Half-unit dose increment pens provide flexibility to achieve target insulin doses especially in young patients with diabetes. JuniorSTAR® has been tested by people with type 1 diabetes (6 to 18 years old), parents and nurses in a non-comparative survey with 167 insulin pen users from five European countries[1]:

- 81% of patients/parents and 86% of nurses agreed it is easy to carry on a daily basis, due of its light weight (~ 34 grams)
- 98% of patients/parents and 94% of nurses agreed it is easy to read due to its large dose display and legible numbers
- Additionally, 91% of patients/parents and 89% of nurses agreed that the dialling back was easy due to its single-step dial back without insulin leakage
- Overall, 93% of survey participants agreed on its ease of use.

JuniorSTAR® meets the new ISO 11608-1:2012 standard and passed all requirements for robustness and dose accuracy. It is offered in three different colors (blue, red and silver), for flexibility and insulin differentiation.

JuniorSTAR® is expected to be available in Europe and Canada throughout 2014.

References:

[1]. Klonoff D et al., Evaluation of the JuniorSTAR® half-unit insulin pen in young people with type 1 diabetes - user perspectives. European Endocrinology. 2013; 9(2):82-5.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.